Related Experiment Video

Updated: Jun 27, 2026

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs
10:44

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs

Published on: May 15, 2019

Toxic epidermal necrolysis in a patient with primary myelofibrosis receiving thalidomide therapy

Marianna Colagrande1, Mauro Di Ianni2, Gino Coletti3

  • 1Chair of Hematology, Department of Internal Medicine and Public Health, University of L'Aquila, Via Vetoio snc, Coppito, 67100, L'Aquila, Italy.

International Journal of Hematology
|December 5, 2008
PubMed

Insights

A patient with JAK2V617F-positive primary myelofibrosis (PMF) developed toxic epidermal necrolysis (TEN) while treated with thalidomide. This is the first reported case of TEN in PMF patients receiving thalidomide therapy.

Area of Science:

  • Hematology
  • Oncology
  • Dermatology

Background:

  • Primary myelofibrosis (PMF) is a myeloproliferative neoplasm associated with anemia, splenomegaly, and often the JAK2V617F mutation.
  • Allogeneic stem cell transplantation offers a cure but carries significant risks, limiting its use.
  • Anti-angiogenic drugs like thalidomide are explored for palliative care in PMF due to bone marrow angiogenesis.

Observation:

  • A patient with JAK2V617F-positive PMF and significant bone marrow neo-angiogenesis was treated with thalidomide.
  • The patient experienced a severe adverse reaction after 20 days of thalidomide treatment.

Findings:

  • The patient developed life-threatening toxic epidermal necrolysis (TEN).
  • This represents the first documented instance of TEN in a primary myelofibrosis patient undergoing thalidomide therapy.

Implications:

  • This case highlights a rare but severe toxicity of thalidomide in PMF patients.
  • Careful monitoring for dermatological adverse events is crucial when using thalidomide in this patient population.
  • Further research may be needed to assess the risk-benefit profile of thalidomide in PMF, especially concerning severe cutaneous reactions.

Related Concept Videos

Graves Disease II: Pathophysiology01:24

Graves Disease II: Pathophysiology

Graves’ disease is an autoimmune disorder characterized by the production of thyroid-stimulating immunoglobulins (TSI) that activate TSH receptors, leading to excessive synthesis and release of thyroid hormones (T3 and T4) and resulting in hyperthyroidism.Among all causes of hyperthyroidism, Graves’ disease is the most common and can happen at any age, though it is more frequent in women. It produces a hypermetabolic state with features such as weight loss, tachycardia, tremor, and heat...
Drug toxicity: Idiosyncratic Reactions01:16

Drug toxicity: Idiosyncratic Reactions

Idiosyncratic drug reactions represent abnormal chemical responses that vary significantly among individuals, ranging from extreme sensitivity to low doses to insensitivity to high doses. These reactions often occur due to the drug's covalent binding with serum proteins, forming a foreign hapten that triggers an immunotoxicological response. The variability in drug reactions has a strong pharmacogenetic foundation, with genetic differences crucial in how individuals metabolize drugs. For...
Diphtheria01:28

Diphtheria

Diphtheria is an acute, toxin-mediated infectious disease that primarily affects the upper respiratory tract. It is caused by Corynebacterium diphtheriae, a Gram-positive, pleomorphic rod that lacks spore-forming capability and exhibits a characteristic club-shaped morphology under microscopic examination. While C. diphtheriae can asymptomatically colonize mucosal surfaces, clinical disease manifests only when the bacterial strain is lysogenized by a specific β-corynephage. This phage...
Drug Toxicity: Allergic Reactions01:30

Drug Toxicity: Allergic Reactions

Drug-related allergies are immune-mediated responses triggered by the administration of pharmacological agents. These hypersensitivity reactions are classified based on the immune mechanisms involved. The four primary types—Type I, II, III, and IV—are mediated by different immunological pathways and exhibit distinct clinical manifestations.Type I Hypersensitivity/ IgE-Mediated Reactions: Immunoglobulin E (IgE) immediately mediates Type I hypersensitivity reactions. Upon initial exposure to a...
Teratogenicity01:07

Teratogenicity

The ability of a drug to produce structural deformations and functional abnormalities in the developing embryo or the fetus is called teratogenicity, and the drug producing this effect is known as a teratogen. Teratogenic effects include stillbirth, miscarriage, intrauterine growth restriction, and neurocognitive delay. A teratogen may affect the embryo at different stages of development, which is important in determining the type and extent of the damage. During blastocyst formation, the early...
Drug Toxicity: Risk factors01:24

Drug Toxicity: Risk factors

Adverse Drug Reactions (ADRs) are potential complications that arise during pharmacotherapy, influenced by multiple risk factors. Age plays a significant role; both neonates and the elderly are at heightened risk due to their respective immature and diminished metabolic and elimination processes. Gender also impacts ADRs, with females experiencing a 1.5 to 1.7-fold greater risk than males, which may be linked to pharmacokinetic, pharmacodynamic, and hormonal differences. Notably, neonates, the...